Literature DB >> 25077423

Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection.

Joshua M Klonoski1, Heather R Hurtig1, Brian A Juber1, Margaret J Schuneman1, Thomas E Bickett1, Joshua M Svendsen1, Brandon Burum2, Thomas A Penfound3, Grigoriy Sereda2, James B Dale3, Michael S Chaussee1, Victor C Huber4.   

Abstract

Influenza virus infections are associated with a significant number of illnesses and deaths on an annual basis. Many of the deaths are due to complications from secondary bacterial invaders, including Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, and Streptococcus pyogenes. The β-hemolytic bacteria S. pyogenes colonizes both skin and respiratory surfaces, and frequently presents clinically as strep throat or impetigo. However, when these bacteria gain access to normally sterile sites, they can cause deadly diseases including sepsis, necrotizing fasciitis, and pneumonia. We previously developed a model of influenza virus:S. pyogenes super-infection, which we used to demonstrate that vaccination against influenza virus can limit deaths associated with a secondary bacterial infection, but this protection was not complete. In the current study, we evaluated the efficacy of a vaccine that targets the M protein of S. pyogenes to determine whether immunity toward the bacteria alone would allow the host to survive an influenza virus:S. pyogenes super-infection. Our data demonstrate that vaccination against the M protein induces IgG antibodies, in particular those of the IgG1 and IgG2a isotypes, and that these antibodies can interact with macrophages. Ultimately, this vaccine-induced immunity eliminated death within our influenza virus:S. pyogenes super-infection model, despite the fact that all M protein-vaccinated mice showed signs of illness following influenza virus inoculation. These findings identify immunity against bacteria as an important component of protection against influenza virus:bacteria super-infection.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bacteria; Influenza; Super-infection

Mesh:

Substances:

Year:  2014        PMID: 25077423      PMCID: PMC4146501          DOI: 10.1016/j.vaccine.2014.06.093

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  90 in total

1.  Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.

Authors:  Mary A Hall; Steven D Stroop; Mary C Hu; Michael A Walls; Mark A Reddish; David S Burt; George H Lowell; James B Dale
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

Review 2.  Correlates of vaccine protection from influenza and its complications.

Authors:  Jonathan A McCullers; Victor C Huber
Journal:  Hum Vaccin Immunother       Date:  2012-01-01       Impact factor: 3.452

Review 3.  The co-pathogenesis of influenza viruses with bacteria in the lung.

Authors:  Jonathan A McCullers
Journal:  Nat Rev Microbiol       Date:  2014-03-03       Impact factor: 60.633

Review 4.  The global burden of group A streptococcal diseases.

Authors:  Jonathan R Carapetis; Andrew C Steer; E Kim Mulholland; Martin Weber
Journal:  Lancet Infect Dis       Date:  2005-11       Impact factor: 25.071

5.  Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H.

Authors:  R D Horstmann; H J Sievertsen; J Knobloch; V A Fischetti
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

6.  Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae.

Authors:  Jonathan A McCullers; Kimberly C Bartmess
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

7.  Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.

Authors:  Karen L Kotloff; Mary Corretti; Kathleen Palmer; James D Campbell; Mark A Reddish; Mary C Hu; Steven S Wasserman; James B Dale
Journal:  JAMA       Date:  2004-08-11       Impact factor: 56.272

8.  Influenza A exacerbates Staphylococcus aureus pneumonia by attenuating IL-1β production in mice.

Authors:  Keven M Robinson; Sun Mi Choi; Kevin J McHugh; Sivanarayana Mandalapu; Richard I Enelow; Jay K Kolls; John F Alcorn
Journal:  J Immunol       Date:  2013-10-02       Impact factor: 5.422

9.  Excess mortality associated with influenza epidemics in Portugal, 1980 to 2004.

Authors:  Baltazar Nunes; Cecile Viboud; Ausenda Machado; Corinne Ringholz; Helena Rebelo-de-Andrade; Paulo Nogueira; Mark Miller
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

10.  Persistence of type-specific antibodies in man following infection with group A streptococci.

Authors:  R C LANCEFIELD
Journal:  J Exp Med       Date:  1959-08-01       Impact factor: 14.307

View more
  11 in total

Review 1.  The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.

Authors:  Amber M Smith; Victor C Huber
Journal:  Viral Immunol       Date:  2017-11-17       Impact factor: 2.257

2.  Binding host proteins to the M protein contributes to the mortality associated with influenza-Streptococcus pyogenes superinfections.

Authors:  Andrea L Herrera; Kuta Suso; Stephanie Allison; Abby Simon; Evelyn Schlenker; Victor C Huber; Michael S Chaussee
Journal:  Microbiology       Date:  2017-10       Impact factor: 2.777

3.  Targeting Colon Cancer Cells with Enzyme-Triggered Casein-Gated Release of Cargo from Mesoporous Silica-Based Nanoparticles.

Authors:  Nisitha Wijewantha; Morgan M Eikanger; Ryan M Antony; Rashaun A Potts; Khosrow Rezvani; Grigoriy Sereda
Journal:  Bioconjug Chem       Date:  2021-10-21       Impact factor: 4.774

Review 4.  Postviral Complications: Bacterial Pneumonia.

Authors:  Jason E Prasso; Jane C Deng
Journal:  Clin Chest Med       Date:  2016-12-13       Impact factor: 2.878

Review 5.  Influenza interaction with cocirculating pathogens and its impact on surveillance, pathogenesis, and epidemic profile: A key role for mathematical modelling.

Authors:  Lulla Opatowski; Marc Baguelin; Rosalind M Eggo
Journal:  PLoS Pathog       Date:  2018-02-15       Impact factor: 6.823

6.  Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.

Authors:  Andrea L Herrera; Christopher Van Hove; Mary Hanson; James B Dale; Rodney K Tweten; Victor C Huber; Diego Diel; Michael S Chaussee
Journal:  PLoS One       Date:  2020-06-23       Impact factor: 3.240

Review 7.  The Association between Invasive Group A Streptococcal Diseases and Viral Respiratory Tract Infections.

Authors:  Andrea L Herrera; Victor C Huber; Michael S Chaussee
Journal:  Front Microbiol       Date:  2016-03-21       Impact factor: 5.640

8.  The Streptococcus pyogenes fibronectin/tenascin-binding protein PrtF.2 contributes to virulence in an influenza superinfection.

Authors:  Andrea L Herrera; Haddy Faal; Danielle Moss; Leslie Addengast; Lauren Fanta; Kathleen Eyster; Victor C Huber; Michael S Chaussee
Journal:  Sci Rep       Date:  2018-08-14       Impact factor: 4.379

9.  TIV Vaccination Modulates Host Responses to Influenza Virus Infection that Correlate with Protection against Bacterial Superinfection.

Authors:  Angela Choi; Ioanna Christopoulou; Xavier Saelens; Adolfo García-Sastre; Michael Schotsaert
Journal:  Vaccines (Basel)       Date:  2019-09-12

10.  Alternaria alternata Accelerates Loss of Alveolar Macrophages and Promotes Lethal Influenza A Infection.

Authors:  Caroline M Percopo; Michelle Ma; Eric Mai; Jamie L Redes; Laura S Kraemer; Mahnaz Minai; Ian N Moore; Kirk M Druey; Helene F Rosenberg
Journal:  Viruses       Date:  2020-08-27       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.